Page 7 of the Zenith October MD&A outlines the loans from Zenith to Resverlogix and may address part of your question as to how RVX is "keeping the lights on".  The loans plus executives and BoD members receiving shares as compensation would help in this regard.

McCaffrey and CFO Caan are listed on the INK reports as receiving shares as compensation for services and Caan sold over half a million shares in 2023. Someone cynical might look at that and say nice way to help keep the share price down in order to maximize share counts for this type of compensation.  The optics of the CFO selling this many shares at this point in time are absolutely brutal IMO and certainly won't help shore up the markets lack of confidence in this company. 

With respect to whether the "business" people at RVX are working full time; the close to zero visible forward progress in the last 4 years leaves one to wonder what these people are doing even on a part time basis. The number of apparent applications/opportunities for Apabetalone, not to mention the 30 other clinic ready compounds, with the corresponding complete lack of business development is a head scratcher for the ages. I have myself never seen such poor performance without senior management being fired for cause. Hopefully (there's that word hope again) the science within the company will soon be able to overcome abysmal management. 

Just for reference I have attached an article from BioPharma dive outlining M&A activity over the last few years.  Times have been hard but not impossible and the table attached at the bottom outlines current market caps relative to IPO sizes. IMO the money and time spent at RVX would rank it close or at the bottom of this list in terms of value (m/c) derived from capital invested.  To me a very telling measure of management's competence as RVX's current m/c is more reflective of a complete science flop as opposed to a company with BTD.

https://www.biopharmadive.com/news/biotech-pharma-deals-merger-acquisitions-tracker/604262/